-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] The results of the seventh batch of national centralized drug procurement plans have been announc.
321 products from 217 companies have obtained the qualifications to be selected, and the average price of the drugs to be selected has been reduced by 4
Up to now, a number of pharmaceutical companies have announced plans to win the bid, including Kelun Pharmaceutical, Huadong Pharmaceutical, Jincheng Pharmaceutical, Sailong Pharmaceutical, Hanyu Pharmaceutical, Hisun Pharmaceutical, Beilu Pharmaceutical, Jingxin Pharmaceutical, Changjiang Health, Warner Pharmaceuticals, Poinsettia, Yuandong Bio, Lifang Pharmaceutical, Puluo Pharmaceutical,e.
For these companies to be selected, some varieties may gain a larger market through centralized procurement, thereby increasing the market share of the company and having a positive impact on the company's future operating performan.
However, the drugs that have won the bid may also affect the profit level of pharmaceutical companies, especially for some competitive products with a large proportion of sales revenue of pharmaceutical companies, after winning the bid for centralized procurement, the overall profit may shrink due to a substantial price reducti.
Affected by the announcement of the results of the proposed election, the stocks of many pharmaceutical companies that planned to win the seventh batch of Guocai rose, and some stocks also fe.
The pharmaceutical companies that plan to win the seventh batch of Guocai have reported good news, and many share prices have risen accordingly (Source: Pharmaceutical Network) Over 3%, many stocks such as Kelun Pharmaceuticals, Beilu Pharmaceuticals, and Warner Pharmaceuticals followed su.
Specifically, as of the close, Huadong Medicine rose 60%, with a quotation of 477 yuan, a turnover of 666 million, a turnover rate of 84%, and a price-earnings (TTM) of 36The company announced that its two subsidiaries planned to win the bid for the seventh batch of national centralized drug procureme.
258 yuan/box), ornidazole tablets (the proposed bid price is 44 yuan/bo.
Warner Pharmaceuticals closed at 356 yuan, an increase of 45%, with a turnover of 148 million, a turnover rate of 80%, and a price-earnings (TTM) of 17In the seventh batch of national procurement of medicines, the company's Mycophenolate Mofetil Capsules are planned to be purchased in a centralized mann.
Changjiang Health closed up 87%, with a quotation of 46 yuan, a turnover of 421 million, a turnover rate of 37%, and a loss in price-earnings (TT.
The pharmaceutical company announced on the evening of July 12 that the wholly-owned secondary subsidiary Hailing Pharmaceuticals, which has passed the consistency evaluation of generic drugs, plans to select the seventh batch of national centralized drug procureme.
Kelun Pharmaceutical closed up 37%, with a quotation of 126 yuan, a turnover of 227 million, a turnover rate of 04%, and a price-earnings (TTM) of 25The company's announcement on the evening of July 12 showed that in the seventh batch of centralized procurement, Kelun Pharmaceuticals, including tirofiban hydrochloride and sodium chloride injection, plans to select 11 dru.
Yuandong Biological closed up 37% at the same time, with a quotation of 593 yuan, a turnover of 62 million, a turnover rate of 85%, and a price-earnings (TTM) of 26The pharmaceutical company announced on the evening of July 12 that the company participated in the bidding for the seventh batch of national centralized drug procurement organized by the State Organization Drug Joint Procurement Offi.
Some of the company's products, ibandronate sodium injection, caffeine citrate injection, memantine hydrochloride sustained-release capsules, and tenofovir fumarate tablets, are planned to be purchased in a centralized mann.
Beilu Pharmaceutical closed at 50 yuan, an increase of 35%, with a turnover of 219 million, a turnover rate of 76%, and a price-earnings (TTM) of 34
Beilu Pharmaceutical announced on the evening of July 12 that the company participated in the seventh batch of national centralized drug procurement organized by the State Organization for Centralized Drug Procurement and Use Joint Procurement Office, and the company's iopamidol injection (100ml: 37g(I)) planned to win the b.
In addition, Jingxin Pharmaceutical closed at 84 yuan, a slight increase of 34%, with a turnover of 668 million, a turnover rate of 05%, and a price-earnings (TTM) of 13Jingxin Pharmaceutical announced on the 13th that Memantine Hydrochloride Sustained-Release Capsules, a drug that the company has passed the quality and efficacy consistency evaluation of generic drugs, is to be selected in this tend.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
321 products from 217 companies have obtained the qualifications to be selected, and the average price of the drugs to be selected has been reduced by 4
Up to now, a number of pharmaceutical companies have announced plans to win the bid, including Kelun Pharmaceutical, Huadong Pharmaceutical, Jincheng Pharmaceutical, Sailong Pharmaceutical, Hanyu Pharmaceutical, Hisun Pharmaceutical, Beilu Pharmaceutical, Jingxin Pharmaceutical, Changjiang Health, Warner Pharmaceuticals, Poinsettia, Yuandong Bio, Lifang Pharmaceutical, Puluo Pharmaceutical,e.
For these companies to be selected, some varieties may gain a larger market through centralized procurement, thereby increasing the market share of the company and having a positive impact on the company's future operating performan.
However, the drugs that have won the bid may also affect the profit level of pharmaceutical companies, especially for some competitive products with a large proportion of sales revenue of pharmaceutical companies, after winning the bid for centralized procurement, the overall profit may shrink due to a substantial price reducti.
Affected by the announcement of the results of the proposed election, the stocks of many pharmaceutical companies that planned to win the seventh batch of Guocai rose, and some stocks also fe.
The pharmaceutical companies that plan to win the seventh batch of Guocai have reported good news, and many share prices have risen accordingly (Source: Pharmaceutical Network) Over 3%, many stocks such as Kelun Pharmaceuticals, Beilu Pharmaceuticals, and Warner Pharmaceuticals followed su.
Specifically, as of the close, Huadong Medicine rose 60%, with a quotation of 477 yuan, a turnover of 666 million, a turnover rate of 84%, and a price-earnings (TTM) of 36The company announced that its two subsidiaries planned to win the bid for the seventh batch of national centralized drug procureme.
258 yuan/box), ornidazole tablets (the proposed bid price is 44 yuan/bo.
Warner Pharmaceuticals closed at 356 yuan, an increase of 45%, with a turnover of 148 million, a turnover rate of 80%, and a price-earnings (TTM) of 17In the seventh batch of national procurement of medicines, the company's Mycophenolate Mofetil Capsules are planned to be purchased in a centralized mann.
Changjiang Health closed up 87%, with a quotation of 46 yuan, a turnover of 421 million, a turnover rate of 37%, and a loss in price-earnings (TT.
The pharmaceutical company announced on the evening of July 12 that the wholly-owned secondary subsidiary Hailing Pharmaceuticals, which has passed the consistency evaluation of generic drugs, plans to select the seventh batch of national centralized drug procureme.
Kelun Pharmaceutical closed up 37%, with a quotation of 126 yuan, a turnover of 227 million, a turnover rate of 04%, and a price-earnings (TTM) of 25The company's announcement on the evening of July 12 showed that in the seventh batch of centralized procurement, Kelun Pharmaceuticals, including tirofiban hydrochloride and sodium chloride injection, plans to select 11 dru.
Yuandong Biological closed up 37% at the same time, with a quotation of 593 yuan, a turnover of 62 million, a turnover rate of 85%, and a price-earnings (TTM) of 26The pharmaceutical company announced on the evening of July 12 that the company participated in the bidding for the seventh batch of national centralized drug procurement organized by the State Organization Drug Joint Procurement Offi.
Some of the company's products, ibandronate sodium injection, caffeine citrate injection, memantine hydrochloride sustained-release capsules, and tenofovir fumarate tablets, are planned to be purchased in a centralized mann.
Beilu Pharmaceutical closed at 50 yuan, an increase of 35%, with a turnover of 219 million, a turnover rate of 76%, and a price-earnings (TTM) of 34
Beilu Pharmaceutical announced on the evening of July 12 that the company participated in the seventh batch of national centralized drug procurement organized by the State Organization for Centralized Drug Procurement and Use Joint Procurement Office, and the company's iopamidol injection (100ml: 37g(I)) planned to win the b.
In addition, Jingxin Pharmaceutical closed at 84 yuan, a slight increase of 34%, with a turnover of 668 million, a turnover rate of 05%, and a price-earnings (TTM) of 13Jingxin Pharmaceutical announced on the 13th that Memantine Hydrochloride Sustained-Release Capsules, a drug that the company has passed the quality and efficacy consistency evaluation of generic drugs, is to be selected in this tend.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
